Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
Laureate Pharma, Inc. Logo. (PRNewsFoto/Laureate Pharma, Inc.)
PRINCETON, NJ UNITED STATES
- Laureate To Manufacture Tolera's Monoclonal Antibody Product Candidate -
PRINCETON, N.J., Oct. 28 /PRNewswire/ -- Laureate Pharma, Inc., a
full-service biopharmaceutical development and protein production company,
today announced that it has entered into a cGMP contract manufacturing
agreement with Tolera Therapeutics, Inc., a biotechnology company that
develops and offers targeted therapies and safer solutions for immune
modulation and related medical needs. According to the agreement, Laureate
will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be
used in clinical trials. Terms of the manufacturing agreement were not
disclosed.
"We are pleased to work closely with Tolera to accelerate their antibody
therapeutics program to clinic," said Robert J. Broeze, Ph. D., President &
Chief Executive Officer of Laureate. "We are committed to providing Tolera
with superior services to help them achieve their manufacturing objectives."
"We are excited to work with Laureate, a company with demonstrated
expertise in biopharmaceutical manufacturing. Their capabilities in both
clinical and commercial-grade materials can support our aggressive development
and commercial plans," said John J. Puisis, President and Chief Executive
Officer of Tolera. "We look forward to our partnership with Laureate in
utilizing their specialized experience in the manufacture of monoclonal
antibodies."
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate Pharma
offers superior bioprocessing services that accelerate new products from
development through production. Laureate provides a wide range of specialized
services from process design and development to full-scale cGMP production,
purification, aseptic filling, testing, validation, analytical services, and
regulatory support. Laureate is focused on two active segments of the
biopharmaceutical industry: monoclonal antibodies and recombinant protein
products. For more information, contact Michael Cavanaugh, Vice President
Sales, Marketing, and Business Development at (609) 919-3400, or
info@laureatepharma.com or visit www.laureatepharma.com.
About Tolera Therapeutics, Inc.
Tolera Therapeutics is a biotechnology company developing novel therapies
for patients and doctors providing more targeted and safer clinical solutions
for immune modulation and related therapies. The company recently closed its
Series A round and intends to commercialize its lead therapeutic agent TOL101
(T-cell modulation) for acute rejection in kidney transplantation, followed by
additional development and commercialization in autoimmune and oncology
applications. For further information, visit www.tolera.com.
